Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Merck
Dow
McKesson
Johnson and Johnson

Last Updated: August 19, 2022

Investigational Drug Information for HIP1402


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for HIP1402?

HIP1402 is an investigational drug.

There have been 5 clinical trials for HIP1402. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2014.

The most common disease conditions in clinical trials are Prostatic Hyperplasia, Hyperplasia, and Erectile Dysfunction. The leading clinical trial sponsors are Hanmi Pharmaceutical Company Limited and [disabled in preview].

There is one US patent protecting this investigational drug and fourteen international patents.

Recent Clinical Trials for HIP1402
TitleSponsorPhase
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects.Hanmi Pharmaceutical Company LimitedPhase 1
PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male VolunteersHanmi Pharmaceutical Company LimitedPhase 1
Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male VolunteersHanmi Pharmaceutical Company LimitedPhase 1

See all HIP1402 clinical trials

Clinical Trial Summary for HIP1402

Top disease conditions for HIP1402
Top clinical trial sponsors for HIP1402

See all HIP1402 clinical trials

US Patents for HIP1402

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
HIP1402 See Plans and Pricing Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof The Regents of the University of California (Oakland, CA) See Plans and Pricing
HIP1402 See Plans and Pricing Therapeutic compounds and methods of use thereof GENENTECH, INC. (South San Francisco, CA) XENON PHARMACEUTICALS INC. (Burnaby, BC, CA) See Plans and Pricing
HIP1402 See Plans and Pricing Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for HIP1402

Drugname Country Document Number Estimated Expiration Related US Patent
HIP1402 European Patent Office EP2981556 2033-04-02 See Plans and Pricing
HIP1402 World Intellectual Property Organization (WIPO) WO2014165513 2033-04-02 See Plans and Pricing
HIP1402 China CN106715418 2034-07-07 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Merck
Dow
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.